Pipeline

ABL105

HomePipelineABL105

  • Pipeline
    ABL105
  • Program Target
    HER2x4-1BB
  • Disease Indication
    Solid Tumor
  • Development Stage
    Late-Stage Research
Summary
ABL105 is a bispecific antibody that targets HER2 and 4-1BB simultaneously. ABL105 crosslinks and activates 4-1BB signaling only in the presence of tumor cells in a HER2 expression-dependent manner, while lacking 4-1BB clustering and T cell activation in normal tissues. In addition, ABL105 blocks HER2 signaling and induces NK cell-mediated cytotoxicity, thereby showing stronger anti-tumor activity. ABL105 significantly inhibits tumor growth and protects mice from tumor re-challenge by inducing tumor specific memory.

MOA of ABL105

ABL105 in the Grabody™-T BsAb Platform activates T-cells only in the Tumor Microenvironment

MOA of ABL105
MOA of ABL105

Tumor Specific 4-1BB Activation

ABL105 activates 4-1BB signaling only in the presence of tumor cells in a HER2 expression-dependent manner

Tumor Specific 4-1BB Activation
Tumor Specific 4-1BB Activation

Strong Anti-Tumor Effect

ABL105 inhibits tumor growth and protects mice from tumor re-challenge by inducing tumor specific memory

Strong Anti-Tumor Effect
좌우스크롤 Strong Anti-Tumor Effect